The importance of @entity1151 ( @entity1151 ) due to @entity49 is recognized in the treatment of @entity455 . We have investigated the physiological effects of plasmin generation in experimental acute @entity1151 using @entity19 deficient in plasminogen ( @entity43312 -/-) or @entity54663 ( @entity54663 -/-). @entity1151 was induced by continuous induction of @entity1211 in the left jugular vein by endothelial injury due to photochemical reaction. The mortality of wild-type @entity19 was 68.8% at 2 h after the initiation of @entity49 and it was significantly reduced in @entity54663 -/- @entity19 (41.7%). In contrast, @entity43312 -/- @entity19 did not survive. Histological evidence of @entity1031 in the lung was obtained in all @entity19 . However, whereas a strict @entity1031 was observed in @entity43312 -/- @entity19 , only a few thrombi were detected in the lungs of @entity54663 -/- @entity19 . Plasma fibrinogen levels measured in @entity19 were not different. When @entity54663 was infused in @entity54663 -/- @entity19 , the mortality was indistinguishable from wild-type @entity19 . Tissue-type plasminogen activator ( @entity865 ) did not reduce the mortality due to acute @entity1151 in wild-type @entity19 . However, in @entity54663 -/- @entity19 , @entity865 (0.52 mg x kg-1) significantly decreased the mortality compared with that of @entity54663 -/- @entity19 without @entity865 . The bleeding time was not significantly prolonged in either type of @entity19 treated with @entity865 . The lack of plasminogen increases the mortality due to acute @entity1151 while a lack of @entity54663 decreases the mortality rate, which can be further reduced by @entity865 administration. Therefore, the combination of inhibition of @entity54663 with thrombolytic therapy could be beneficial in the treatment of acute @entity1151 .

XXXX plays a significant role in @entity1151 .

@entity455 :: ('MESH:D014652', 'Disease') :: ['vascular diseases'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity54663 :: ('18816(Tax:10090)', 'Gene') :: ['alpha2-AP', 'alpha2-antiplasmin'] @entity49 :: ('MESH:D019851', 'Disease') :: ['venous thrombosis'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['PE', 'pulmonary embolism'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism'] @entity865 :: ('CHEBI:61432', 'Chemical') :: ['tPA'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thrombus'] @entity43312 :: ('18815(Tax:10090)', 'Gene') :: ['Plg']
@entity54663 :: (18816(Tax:10090),Gene) :: ['Alpha2-antiplasmin']
